 DALLAS--BUSINESS WIRE--Taysha Gene Therapies, Inc. Nasdaq: TSHA, a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system CNS in both rare and large patient populations, and UT Southwestern Medical Center UTSW today announced the launch of an innovation fund to discover and develop novel gene therapy candidates and next-generation technologies for monogenic diseases of 